Atlas Trials

Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)

Clinical trial NCT07204327 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07204327
Sponsor
Zhongda Hospital
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Unresectable Hepatocellular Carcinoma
Start date
2020-10-28
Primary completion
2025-10-31
Enrollment
1136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.